Company intelligence / Profile preview

Deimos

San Francisco, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Deimos is an early-stage biotechnology company focused on developing novel therapeutics for neurological and psychiatric disorders. The company leverages a proprietary platform to identify and optimize small molecule candidates that target specific pathways involved in brain function and disease. Deimos aims to address significant unmet medical needs in areas such as depression, anxiety, and neurodegenerative diseases. By combining advanced computational tools with deep biological insights, the company is building a pipeline of innovative drug candidates designed to improve patient outcomes and quality of life.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Deimos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deimos.

Explore the full profile